20 Osteogenesis Imperfecta Clinical Trials in Palo Alto, CA (2026)

Q: How do I join a clinical trial in Palo Alto?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Palo Alto research site will contact you.

Recruiting Osteogenesis Imperfecta Studies in Palo Alto

NCT02418442Recruiting

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARR...

Palo Alto, CA20,000 participantsDuke University

View Study Details

NCT02848274Recruiting

ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various ins...

Palo Alto, CA2,000 participantsStanford University

View Study Details

NCT04375033Recruiting

A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder

VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous (in the belly area) formulation of buprenorphine at a target dose of 300mg is superior in retaining Veterans in opioid tre...

Palo Alto, CA952 participantsVA Office of Research and Development

View Study Details

NCT05750498Recruiting

A-LiNK: Improving Outcomes in Autoimmune Liver Disease

The Autoimmune Liver disease Network for Kids (A-LiNK) is a multi-institutional group with the mission to deliver the best care to kids with pediatric autoimmune liver disease (AILD). This study will...

Palo Alto, CA800 participantsChildren's Hospital Medical Center, Cincinnati

View Study Details

NCT05865301Recruiting

Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy

To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozog...

Palo Alto, CA500 participantsStanford University

View Study Details

NCT03816345Recruiting

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, an...

Palo Alto, CA300 participantsNational Cancer Institute (NCI)

View Study Details

NCT06475989Recruiting

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatmen...

Palo Alto, CA264 participantsECOG-ACRIN Cancer Research Group

View Study Details

NCT03850574Recruiting

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelod...

Palo Alto, CA240 participantsAptose Biosciences Inc.

View Study Details

NCT06393712Recruiting

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patient...

Palo Alto, CA200 participantsAlnylam Pharmaceuticals

View Study Details

NCT06655246Recruiting

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) ...

Palo Alto, CA157 participantsKura Oncology, Inc.

View Study Details

NCT06007690Recruiting

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melano...

Palo Alto, CA100 participantsAura Biosciences

View Study Details

NCT07003100Recruiting

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

This study is being done to assess mogamulizumab-associated rash in patients diagnosed with mycosis fungoides or sezary syndrome and treated with standard of care mogamulizumab. One of the most common...

Palo Alto, CA100 participantsCity of Hope Medical Center

View Study Details

NCT06902519Recruiting

Study of GS-0151 in Participants With Rheumatoid Arthritis

The goal of this clinical study is to learn more about the study drug GS-0151. The study is done to find how safe, well-tolerated the drug is. This will also assess how the drug is absorbed, modified,...

Palo Alto, CA75 participantsGilead Sciences

View Study Details

NCT02923011Recruiting

Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas

Osteoid osteomas are painful, benign bone tumors that occur most frequently in young males between ages 10 and 20 years. The goal of the proposed study is based on the premise that MRgFUS is noninferi...

Palo Alto, CA56 participantsMatthew Bucknor

View Study Details

NCT05949099Recruiting

Study of Cryoablation and Nirogacestat for Desmoid Tumor

The primary purpose of this protocol is Systemic therapy with oral study agent, nirogacestat, followed by a single cryoablation procedure....

Palo Alto, CA28 participantsNam Bui

View Study Details

NCT06643884Recruiting

Suprachoroidal Administration in Subjects With Choroidal Metastasis From Breast or Lung Primary Tumors

The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with choroidal metastasis from breast or lung primary tumors....

Palo Alto, CA24 participantsAura Biosciences

View Study Details

NCT06551584Recruiting

Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis....

Palo Alto, CA24 participantsStanford University

View Study Details

NCT06561152Recruiting

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

To determine the efficacy of the combination of tagraxofusp, cladribine, and cytarabine....

Palo Alto, CA20 participantsStanford University

View Study Details

NCT07306832Recruiting

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't respond to treatment. This study will assess the adverse even...

Palo Alto, CA18 participantsAbbVie

View Study Details

NCT05188170Recruiting

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia....

Palo Alto, CA16 participantsStanford University

View Study Details

About Osteogenesis Imperfecta Clinical Trials in Palo Alto

Osteogenesis imperfecta is a group of genetic disorders mainly affecting the bones, causing them to break easily, often from little or no apparent cause. It is caused by defects in collagen production. Treatment includes bisphosphonates, physical therapy, and surgical rodding.

There are currently 20 osteogenesis imperfecta clinical trials recruiting participants in Palo Alto, CA. These studies are seeking a combined 25,874 participants. Research is being sponsored by Duke University, Stanford University, VA Office of Research and Development and 12 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Osteogenesis Imperfecta Clinical Trials in Palo Alto — FAQ

Are there osteogenesis imperfecta clinical trials in Palo Alto?

Yes, there are 20 osteogenesis imperfecta clinical trials currently recruiting in Palo Alto, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Palo Alto?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Palo Alto research site will contact you about next steps.

Are clinical trials in Palo Alto free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Palo Alto studies also compensate for your time and travel.

What osteogenesis imperfecta treatments are being tested?

The 20 active trials in Palo Alto are testing new therapies including novel drugs, biologics, and treatment approaches for osteogenesis imperfecta.

Data updated July 13, 2026 from ClinicalTrials.gov